Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
541
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma

Lorena Panaitea Department of Medicine, University of Washington, Seattle, WA, USAView further author information
,
Qian “Vicky” Wub Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Jenna Voutsinasb Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Erin Mullaneb Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Victor A. Chowa Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Ryan C. Lyncha Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Chaitra S. Ujjania Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Stephen D. Smitha Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Ajay K. Gopala Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Christina Poha Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Lorenzo Iovinob Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Cameron J. Turtlea Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
David G. Maloneya Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-8477-6919View further author information
ORCID Icon,
Brian G. Tilla Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
,
Jordan Gauthiera Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USAView further author information
&
Mazyar Shadmana Department of Medicine, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutch, Seattle, WA, USACorrespondence[email protected]
View further author information
 show all
Pages 2918-2922 | Received 23 Jan 2022, Accepted 20 Jun 2022, Published online: 09 Jul 2022

References

  • Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Tisagenlecleucel in adult patients with aggressive b-cell non-hodgkin lymphoma (BELINDA). Available from: https://clinicaltrials.gov/ct2/show/NCT03570892
  • A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Available from: https://clinicaltrials.gov/ct2/show/NCT03575351
  • Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7). Available from: https://clinicaltrials.gov/ct2/show/NCT03391466
  • Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095–3106.
  • Yescarta (Axicabtagene ciloleucel) [package insert] Kite Pharma. U.S. Food and Drug Administration 2019.
  • Kymriah (tisagenlecleucel) [package insert]. Novartis. U.S. Food and Drug Administration 2019.
  • Schaefer AS, Maakaron J, Hoelscher T, et al. Cytopenias after chimeric antigen receptor T-Cells (CAR-T) infusion; patterns and outcomes. Biol Blood Marrow Transpl. 2019;25(3):S171.
  • Byrne M, Oluwole OO, Savani B, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(11):e344–e351.
  • Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019;94(8):E209–E213.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
  • Van de Geer SB, Ritov YA, Dezeure R. On asymptotically optimal confidence regions and tests for high-dimensional models. Ann Stat. 2014;42(3):1166–1202.
  • Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57(1):289–300.
  • Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643–1650.
  • Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554.
  • Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776–3787.
  • Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4):940–943.
  • Juluri KH, Mullane E, Turtle CJ, et al. Factors associated with impaired hematopoietic recovery after CD19-Targeted CAR-T cell therapy. Biol Blood Marrow Transpl. 2020;26(3):S313.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.